Cardinal Health, Inc. vs Samsung Electronics Co., Ltd.: Strategic Comparison

This in-depth comparison examines Cardinal Health, Inc. and Samsung Electronics Co., Ltd. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Cardinal Health, Inc. on its own, evaluating Samsung Electronics Co., Ltd., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Cardinal Health, Inc. and Samsung Electronics Co., Ltd. is widest.

On the headline numbers, Cardinal Health, Inc. reports annual revenue of $254.2B against ~$236.9B for Samsung Electronics Co., Ltd., while their respective market capitalizations stand at $56.0B and $1.33T. Cardinal Health, Inc. is headquartered in United States and Samsung Electronics Co., Ltd. in South Korea, and those different home markets shape how each company competes.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

Samsung Electronics Co., Ltd.: Samsung Electronics, based in Suwon, is the flagship company of the Samsung Group and South Korea's most valuable listed company. It is the world's largest memory chipmaker and one of the two largest smartphone vendors. Its market value passed $1 trillion in May 2026 and was about $1.33 trillion in late September 2026, after its shares more than tripled in a year on AI memory demand. The company is led by co-CEOs Jun Young-hyun (semiconductors) and TM Roh (devices), with Jay Y. Lee as Executive Chairman.

Cardinal Health, Inc. and Samsung Electronics Co., Ltd. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Cardinal Health, Inc. and Samsung Electronics Co., Ltd..

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

Samsung Electronics Co., Ltd. business model: Samsung earns money from two groups of businesses. Device Solutions (DS) makes and sells memory (DRAM, HBM, NAND), System LSI chips such as Exynos processors and ISOCELL image sensors, and contract foundry manufacturing. In Q2 2026, DS produced ~$90.5 billion (KRW 127.5 trillion) of the company's ~$122 billion (KRW 171.5 trillion) revenue and ~$63.3 billion (KRW 89.2 trillion) of its ~$63.5 billion (KRW 89.5 trillion) operating profit. Device eXperience (DX) sells Galaxy phones, tablets, wearables, TVs, monitors and home appliances, plus network equipment. Separately consolidated subsidiaries add OLED panels from Samsung Display, sold to Apple and other phone makers, and automotive and audio electronics from Harman.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Cardinal Health, Inc. stack up against those of Samsung Electronics Co., Ltd..

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

Samsung Electronics Co., Ltd. competitive advantage: Samsung's edge is manufacturing scale and breadth. It is the largest memory producer and one of only three major DRAM makers, alongside SK hynix and Micron. That lets it capture pricing upswings like the 2026 AI-driven shortage. It also owns component businesses (memory, OLED through Samsung Display, image sensors) that sell to rivals as well as to its own Galaxy devices, so it earns money even when competitors' products win.

Future prospects matter as much as current results. The growth strategies below explain how Cardinal Health, Inc. and Samsung Electronics Co., Ltd. each plan to expand from here.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

Samsung Electronics Co., Ltd. growth strategy: Samsung's growth plan centers on AI memory: ramping HBM4 for Nvidia and AMD accelerators, developing HBM4E, and adding DRAM capacity at Pyeongtaek. In foundry it is pursuing 2nm gate-all-around production and building its Taylor, Texas fab to win customers from TSMC. On the device side it relies on Galaxy AI features, foldables and premium TVs to defend share against Apple and Chinese brands.

A closer look at the financial trajectory of Cardinal Health, Inc. and Samsung Electronics Co., Ltd. rounds out the comparison.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.

Samsung Electronics Co., Ltd.: Samsung's earnings follow the memory cycle. Revenue fell from ~$215 billion (KRW 302.2 trillion) in 2022 to ~$184 billion (KRW 258.9 trillion) in 2023 during a chip downturn, then recovered to ~$214 billion (KRW 300.9 trillion) in 2024 and ~$237 billion (KRW 333.6 trillion) in 2025, when net income reached about $31.5 billion (KRW 44.3 trillion). In 2026, AI server demand created a memory shortage. Q1 operating profit of ~$40.6 billion (KRW 57.2 trillion) exceeded the full-year 2025 total, and Q2 reached ~$63.5 billion (KRW 89.5 trillion) on ~$122 billion (KRW 171.5 trillion) revenue. Higher memory costs also squeezed Samsung's own devices: the MX and Networks unit lost ~$497 million (KRW 0.7 trillion) in Q2 2026 on ~$23.6 billion (KRW 33.2 trillion) revenue.